Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc.'s (NASDAQ:AMGN) Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for adult patients with chronic rhinosinusitis with ...

GSK’s depemokimab shows strong potential for United States Food and Drug Administration approval in asthma and chronic ...

In this edition of The People’s Pharmacy, Joe and Teresa Graedon also hear from a reader who lost their sense of smell after using zinc to treat a cold.

The latest advancements in global biosimilar access include new treatments, strategic partnerships, and competitive market ...

Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...

The approval for the CRSwNP indication was based on data from the randomized, double-blind, placebo-controlled WAYPOINT trial.

Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation THOUSAND OAKS, Calif., Oct. 17, 2025 ...

The FDA approved Amgen's and AstraZeneca's drug to treat chronic rhinosinusitis with nasal polyps, an inflammatory condition of the sinuses and nasal passages. The companies said the approval was ...

The U.S. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic inflammatory sinus ...

The FDA on Friday approved a new biologic as add-on maintenance treatment for inadequately controlled chronic rhinosinusitis ...